Marc Lesnick

Dr. Lesnick has deep experience in managing global research and development programs from pre-clinical stage through Phase 3. His background spans a number of therapeutic categories including psychiatry, infectious disease, endocrinology, oncology and allergy. Before co-founding Park Therapeutics, Marc held various executive roles at Spruce Biosciences, QED Therapeutics, Cascadian Therapeutics and Shionogi, Inc., among others, where he focused heavily on regulatory affairs and quality assurance, successfully progressing numerous clinical programs through to U.S. FDA and ex-U.S. approvals. Marc received his Bachelor of Science in Biochemistry and Molecular Biology from the University of California at Santa Cruz and completed his Ph.D. in Biology at the University of Oregon.